Congratulations to #Immusoft on its $4M grant from #CIRM, and congrats to its co-founder & inventor: Matt Scholz: bwnews.pr/319mJn7

#BioWatch update on #Capricor $CAPR on its #HOPE-3 Trial + more. Read at: bit.ly/3GXZpYL

BioWatch Update on #Capricor Therapeutics $CAPR including thots on recent licensing agreement. Read at: bit.ly/3rrD8xj

#BioWatch News commentary on #Corcept's $CORT Q4-2021 / FY2021 Update. Read at bit.ly/3s4TiNH

#BioWatch commentary on #Capricor's $CORT Q4 & FY 2021 results. Read at bit.ly/3J2pNBP

#BioWatch commentary on #Corcept's $CORT ovarian cancer results and program update. Read at: bit.ly/3iU4K9s

#BioWatch takes a 2nd look - Corcept's ovarian cancer results - The Median is not the Message. Read at: bit.ly/3715DKv

BioWatch News' May 2022 Updates on #Corcept Therapeutics $CORT (bit.ly/3wzauwH) and #Capricor Therapeutics $CAPR (bit.ly/3LzMBcF). Enjoy!

#BioWatch News' commentary on #Corcept's $CORT updated ovarian cancer results & pivotal trial design. Plus an added bonus: major Phase 2 ALS trial design. Read at: bit.ly/3mjGhMv

#BioWatch #Capricor Therapeutics $CAPR - Extension Data Builds Case - #Duchenne Muscular Dystrophy - Read at: bit.ly/3ynDxo1

Check out my latest article: Capricor DMD Extension Results - Conference Call: O-LE! O-LE! linkedin.com/pulse/capricor… via LinkedIn

BioWatch Commentary: Capricor Therapeutics - Conference Call - One Year Extension Results - DMD - Read at: bit.ly/3HUWFN8

#Corcept Therapeutics $CORT - Special #BioWatch Update - Psychiatric & Neurological Indications - Read at bit.ly/3Q9ljMX

#BioWatch Update - #Corcept $CORT - Q2-2022 - Trio of Clinical Results Coming. Read at: bit.ly/3bA9hxt

#Capricor Therapeutics' $CAPR Q2-2022 Update - #BioWatch's commentary at: bit.ly/3bKbR46

#BioWatchNews special update on #Capricor $CAPR. Read at: bit.ly/3Sd1tBv

#BioWatch News Commentary on #Corcept's $CORT Q3-2022 Update & Guidance. Read at: bit.ly/3fBgvn4

#BioWatch's commentary on #Capricor's $CAPR Q3-2022 Update. Read at: bit.ly/3E2d8xJ

#BioWatch update on #Capricor $CAPR concerning positive 18-month OLE results of #CAP1002 to treat #Duchenne #DMD. Read at: bit.ly/3YlNwoA

#BioWatch's commentary on $CAPR #Capricor - #NipponShinyaku license expansion for #Duchenne #DMD. Read at: bit.ly/3IUCfWE